Search results
Results from the WOW.Com Content Network
The Medicaid Drug Rebate Program is a program in the United States that was created by the Omnibus Budget Reconciliation Act of 1990 (OBRA'90).. The program establishes mandatory rebates that drug manufacturers must pay state Medicaid agencies related to the dispensing of outpatient prescription drugs covered by Medicaid.
Misclassification under the Medicaid Drug Rebate Program: False Claims Act: 2010 14 (tie) 13 Trileptal: Novartis [18] $465,000,000 $390 million ($465 million with co-defendant settlements) Off-label promotion/kickbacks False Claims Act/FDCA 2008 17 14 Actiq/Gabitril/Provigil: Cephalon [19] $425,000,000 $375 million civil ($425 million with ...
It required pharmaceutical manufacturers to provide rebates for medication purchases, based on sales to Medicaid beneficiaries, as a condition of having their products covered by Medicaid. [3] The amount of the rebates paid to the states were based on a "best price" calculation that did not take into account the discounted prices that ...
Pandemic-ravaged hospitals that serve poor and low-income New Yorkers will get $3.2 billion in aid under the recently approved state budget for 2025, according to Gov. Kathy Hochul's estimates ...
As many as 3 million New Yorkers may be fraudulently reaping taxpayer-funded Medicaid and other public health insurance benefits at a potential cost of $20 billion a year, a staggering new study ...
False Claims Act, Medicaid Rebate Statute 2007 Purdue Pharma [15] $601 million Off-label promotion Oxycontin: False Claims Act 2010 Allergan [16] $600 million Off-label promotion Botox: False Claims Act, FDCA 2010 AstraZeneca [17] $520 million Off-label promotion, kickbacks Seroquel: False Claims Act 2007 Bristol-Myers Squibb [18] $515 million
The company expects the number of consumers served to be 50.97 million-51.32 million, including 8.4 million-8.45 on Medicare Advantage and 7.675 million–7.775 million on Medicaid.
The Medicaid drug rebate for brand name drugs, paid by drug manufacturers to the states, is increased to 23.1% (except for the rebate for clotting factors and drugs approved exclusively for pediatric use, which increases to 17.1%), and the rebate is extended to Medicaid managed care plans; the Medicaid rebate for non-innovator, multiple source ...